Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected ... Moving checkpoint inhibitors further up the treatment pathway into earlier adjuvant and neoadjuvant ...